Aethlon Medical Announces Issuance of Virus Treatment Patent

[Guest guest]

Aethlon Medical Announces Issuance of Virus Treatment Patent

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Patent No. 7,226,429 has been issued to Aethlon Medical by the United States Patent and Trademark Office (USPTO). The patent, "Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis," is integral to Aethlon's intellectual property portfolio as it defines methods that allow the Aethlon Hemopurifier® to selectively capture a broad-spectrum of viruses from blood.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier®, a first-in-class medical device to treat infectious disease. The Hemopurifier® is an innovative platform technology targeted to be a broad-spectrum treatment solution for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier® are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon has previously demonstrated safety of the Hemopurifier® in a 24-treatment human study, and most recently submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to initiate human studies of the Hemopurifier® as a treatment countermeasure against select category "A" bioterror threats. Category "A" threats are defined by the CDC as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; may cause public panic and social disruption; and require special action for public health preparedness. Additional information on Aethlon Medical and its Hemopurifier® technology can be accessed at www.aethlonmedical.com

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Source: Business Wire

http://www.redorbit.com/news/health/966303/aethlon_medical_announces_issuance_of_virus_treatment_patent/index.html?source=r_health

[Guest guest]

June 2008

Fwd: Aethlon Medical Announces Issuance of Virus Treatment Patent

Aethlon Medical Announces Issuance of Virus Treatment Patent

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Patent No. 7,226,429

has been issued to Aethlon Medical by the United States Patent and Trademark

Office (USPTO). The patent, " Method for Removal of Viruses from Blood by

Lectin Affinity Hemodialysis, " is integral to Aethlon's intellectual

property portfolio as it defines methods that allow the Aethlon

Hemopurifier® to selectively capture a broad-spectrum of viruses from blood.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier®, a first-in-class

medical device to treat infectious disease. The Hemopurifier® is an

innovative platform technology targeted to be a broad-spectrum treatment

solution for drug and vaccine resistant bioweapons, naturally evolving

pandemic threats, and chronic infectious disease conditions including

Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative

studies to demonstrate utility of the Hemopurifier® are being conducted with

researchers at the Government of India's National Institute of Virology

(NIV), The Centers for Disease Control and Prevention (CDC), The United

States Army Medical Research Institute of Infectious Diseases (USAMRIID),

and The Southwest Foundation for Biomedical Research (SFBR). Aethlon has

previously demonstrated safety of the Hemopurifier® in a 24-treatment human

study, and most recently submitted an Investigational Device Exemption (IDE)

to the U.S. Food and Drug Administration (FDA) requesting permission to

initiate human studies of the Hemopurifier® as a treatment countermeasure

against select category " A " bioterror threats. Category " A " threats are

defined by the CDC as agents that pose a risk to national security; are

easily disseminated or transmitted from person to person; result in high

mortality rates; may cause public panic and social disruption; and require

special action for public health preparedness. Additional information on

Aethlon Medical and its Hemopurifier® technology can be accessed at

www.aethlonmedical.com

Certain of the statements herein may be forward-looking and involve risks

and uncertainties. Such forward-looking statements involve assumptions,

known and unknown risks, uncertainties and other factors which may cause the

actual results, performance or achievements of Aethlon Medical, Inc. to be

materially different from any future results, performance, or achievements

expressed or implied by the forward-looking statements. Such potential risks

and uncertainties include, without limitation, the Company's ability to

raise capital when needed, the Company's ability to complete the development

of its planned products, the ability of the Company to obtain FDA and other

regulatory approvals permitting the sale of its products, the Company's

ability to manufacture its products and provide its services, the impact of

government regulations, patent protection on the Company's proprietary

technology, product liability exposure, uncertainty of market acceptance,

competition, technological change, and other risk factors. In such

instances, actual results could differ materially as a result of a variety

of factors, including the risks associated with the effect of changing

economic conditions and other risk factors detailed in the Company's

Securities and Exchange Commission filings.

Source: Business Wire

http://www.redorbit.com/news/health/966303/aethlon_medical_announces_issuance_of\

_virus_treatment_patent/index.html?source=r_health